Cell News and Research

RSS

Study identifies cytokine signaling pathway that induces breakdown of disused skeletal muscle

A new study in the Journal of Cell Biology identifies a cytokine signaling pathway that induces the breakdown of disused skeletal muscle. Blocking this pathway could prevent immobilized patients from losing their muscle tissue.

23 Mar 2010

Treating RNA segment in wounds may increase protein levels for growth of skin cells

Scientists have determined that chronic wounds might have trouble healing because of the actions of a tiny piece of a molecular structure in cells known as RNA.

23 Mar 2010

NPR's Car Talk guys team up with University of Utah to launch Driver Distraction Center

NPR's Car Talk guys, Tom and Ray Magliozzi, may be a couple of motor mouths, but they always put a lid on using cell phones behind the wheel. The perennial jokesters confirm their serious commitment to addressing the issue of devices that take a driver's focus off the road by teaming with the University of Utah to launch the Driver Distraction Center at their web site: cartalk.com/distraction.

23 Mar 2010

Blocking Bak inhibitors can be promising strategy in limiting resistance of cancer to TRAIL

The TRAIL ligand is a promising anticancer agent that preferentially kills tumor cells without apparent damage to healthy cells. Many cancers exhibit resistance to TRAIL, however, thus limiting its therapeutic potential.

23 Mar 2010

CT colonography screening identifies unsuspected cancer outside of colon

A new, large-scale study of more than 10,000 adults found that more than one in every 200 asymptomatic people screened with CT colonography, or virtual colonoscopy, had clinically unsuspected malignant cancer and more than half of the cancers were located outside the colon. The findings were published in the April issue of the journal Radiology.

23 Mar 2010

Walnuts affect genes related to prostate tumor growth: Study

Walnut consumption slows the growth of prostate cancer in mice and has beneficial effects on multiple genes related to the control of tumor growth and metabolism, UC Davis and the U.S. Department of Agriculture Western Regional Research Center in Albany, Calif. have found.

23 Mar 2010

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

A new understanding of a certain cell in the immune system may help guide scientists in creating better flu vaccines, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, today announced it completed financing in which the company raised $15.5 million.

23 Mar 2010

GSK notifies regulatory authorities of the presence of PCV-1 in Rotarix vaccine

GlaxoSmithKline today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1 in its oral rotavirus vaccine, Rotarix™. PCV-1 does not multiply in humans and is not known to cause illness in humans.

23 Mar 2010

Meridian Bioscience seeks FDA marketing clearance for illumigene C. difficile molecular diagnostic test

Meridian Bioscience, Inc. announced today that it has submitted a 510(k) application to the United States Food and Drug Administration for marketing clearance of its new, simple molecular diagnostic test, illumigene™ C. difficile. illumigene is a simplified new technology platform, based upon loop amplification (LAMP) that makes molecular diagnostic testing possible for any size laboratory.

23 Mar 2010

GUMC scientists awarded five-year $7.5M grant to perfect treatment of breast cancer

Scientists at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center were awarded a five-year $7.5 million grant to tease apart - in the most comprehensive way ever devised -the role of a single protein receptor in breast cells in cancer development and treatment.

22 Mar 2010

EHSI closes funding agreement with Celulas Genetica

Emerging Healthcare Solutions, Inc. announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in up to 20% of earnings produced by Celulas Genetica when the agreement is funded in full.

22 Mar 2010

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

22 Mar 2010

JDRF, Pfizer, Hadassah Medical Organization, The Hebrew University of Jerusalem form diabetes research collaboration

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes.

22 Mar 2010

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Cancer Research Technology has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the 'protein kinase C' superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Zenyaku Kogyo receives license to Theraclone Sciences' influenza monoclonal antibody program

Theraclone Sciences, Inc., announced that Zenyaku Kogyo Co. Ltd., has exercised its option for an exclusive license in the Japan territory to Theraclone’s influenza monoclonal antibody program. The collaboration utilizes Theraclone’s I-STAR™ technology to discover broadly protective monoclonal antibodies for the treatment of pandemic influenza and severe seasonal influenza.

22 Mar 2010

Investment report on Gentium from InvestorSoup.com

InvestorSoup.com announces an investment report featuring Gentium SpA. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

22 Mar 2010

Cell News and Research

Study identifies cytokine signaling pathway that induces breakdown of disused skeletal muscle

Treating RNA segment in wounds may increase protein levels for growth of skin cells

NPR's Car Talk guys team up with University of Utah to launch Driver Distraction Center

Blocking Bak inhibitors can be promising strategy in limiting resistance of cancer to TRAIL

CT colonography screening identifies unsuspected cancer outside of colon

Walnuts affect genes related to prostate tumor growth: Study

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

GSK notifies regulatory authorities of the presence of PCV-1 in Rotarix vaccine

Meridian Bioscience seeks FDA marketing clearance for illumigene C. difficile molecular diagnostic test

GUMC scientists awarded five-year $7.5M grant to perfect treatment of breast cancer

EHSI closes funding agreement with Celulas Genetica

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

JDRF, Pfizer, Hadassah Medical Organization, The Hebrew University of Jerusalem form diabetes research collaboration

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

ChemoCentryx undertakes Phase II clinical trial of CCX140

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Zenyaku Kogyo receives license to Theraclone Sciences' influenza monoclonal antibody program

Investment report on Gentium from InvestorSoup.com

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News